<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5286377 Figure_1-A</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Four representative images of RHOB immunostaining in human non-small-cell lung cancers. Figures correspond to the percentage of tumor analyzed.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_1-B</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Characteristics of 96 patients with an EGFR-activating mutation who were treated with EGFR-TKI. Each column corresponds to one patient. Data include general characteristics (stage at diagnosis, age, sex, tobacco usage, position of EGFR mutation, TKI type), progression-free survival (PFS; lower graph) and intensity of RHOB staining as determined by immunohistochemistry (null: 0, weak: +, moderate: ++ and high: +++).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_1-C</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Representative scans of patients with low or high RHOB-expressing lung tumors, before and after erlotinib treatment. Red arrows indicate lung tumors.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_1-D</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Progression-free survival of erlotinib-treated patients with EGFR-mutated lung tumors, according to RHOB expression, assessed by immunohistochemistry (low RHOB group = negative + weak staining; high RHOB group = moderate + high staining).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_1-E-F</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 1-E-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E-F</infon>
    <passage>
      <offset>0</offset>
      <text>E. Progression-free survival of patients who received EGFR-TKi as first-line therapy (n=63). F. Progression-free survival of patients who received EGFR-TKi as 2nd-line (n=28), 3rd-line (n=3) or 4th-line (n=2) therapy.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_1-G</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 1-G</infon>
    <infon key="sourcedata_figure_dir">Figure_1-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. RHOB immunostaining score evolution in EGFR-mutated lung tumors before treatment and after EGFR-TKI relapse.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_2-A-B</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 2-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A. Representative H&amp;E staining of whole lungs from EGFRL858R/Rhob-/-, EGFRL858R/Rhob+/- and EGFRL858R/Rhob+/+ mice treated or not with erlotinib (12.5 mg/kg/day) for four days. Scale bar: 5 mm. B. Quantification of the tumor/lung ratio. n=7 for each group except for EGFRL858R/Rhob+/- placebo (n=6).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_2-C-D</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 2-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C. Representative Ki67 immunostaining of EGFRL858R/Rhob-/-, EGFRL858R/Rhob+/- and EGFRL858R/Rhob+/+ mice treated or not with erlotinib (12.5 mg/kg/day) for four days (scale bar: 50 &#181;m), and the corresponding quantification (D). Three independent zones/mice lung were used for quantification. n=21 (7 mice) for each group except for EGFRL858R/Rhob+/- placebo (n=18; 6 mice).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_2-E</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 2-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Immunostaining of cleaved caspase-3 in lung tumors from EGFRL858R/Rhob+/+ or EGFRL858R/Rhob-/- mice treated for 24 h with erlotinib at 12.5 mg/kg. Scale bar: 50 &#181;m. (**: p&lt;0.001 vs. placebo; ***: p&lt;0.0001 vs. placebo).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-A-1</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-A-1</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A-1</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were (A) transfected with two siRNA against RHOB (siB1, siB2) then treated with increasing doses of erlotinib. The surviving cell fraction was determined by an MTS assay after 72 h and compared to untreated cells.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-A-2</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-A-2</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A-2</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were (A) transfected with two siRNA against RHOB (siB1, siB2). RHOB overexpression was monitored by western blotting. (***: p&lt;0.0001 vs. control cells). Data are representative of at least three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-B-1</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-B-1</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B-1</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were (B) transduced with control (AdCont) or RHOB-overexpressing adenoviruses (AdRHOB) then treated with increasing doses of erlotinib. The surviving cell fraction was determined by an MTS assay after 72 h and compared to untreated cells.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-B-2</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-B-2</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B-2</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were (B) transduced with control (AdCont) or RHOB-overexpressing adenoviruses (AdRHOB). RHOB overexpression was monitored by western blotting. (***: p&lt;0.0001 vs. control cells). Data are representative of at least three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-C-1</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-C-1</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C-1</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were (C) both transfected with siRNA and transduced by adenoviruses; then treated with increasing doses of erlotinib. The surviving cell fraction was determined by an MTS assay after 72 h and compared to untreated cells.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-C-2</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-C-2</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C-2</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were (C) both transfected with siRNA and transduced by adenoviruses; then treated with increasing doses of erlotinib. RHOB overexpression was monitored by western blotting. (***: p&lt;0.0001 vs. control cells). Data are representative of at least three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-D-E-F</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-D-E-F</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D-E-F</infon>
    <passage>
      <offset>0</offset>
      <text>Erlotinib IC50 values were quantified in RHOB-overexpressing or RHOB-depleted (D) HCC827 cells, (E) HCC2935 cells and (F) H3255 cells, as determined by an MTS assay after 72 h treatment. RHOB overexpression or inhibition was monitored by western blotting for each condition.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-G-1</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-G-1</infon>
    <infon key="sourcedata_figure_dir">Figure_3-G-1</infon>
    <passage>
      <offset>0</offset>
      <text>G. HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing adenoviruses (AdRHOB) at an increasing multiplicity of infection (MOI), then erlotinib IC50 values were determined after 72 h by an MTS assay and a correlation analysis was performed.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_3-G-2</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 3-G-2</infon>
    <infon key="sourcedata_figure_dir">Figure_3-G-2</infon>
    <passage>
      <offset>0</offset>
      <text>G. HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing adenoviruses (AdRHOB) at an increasing multiplicity of infection (MOI). RHOB overexpression was monitored by western blotting. (***: p&lt;0.0001 vs. control cells). Data are representative of at least three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_4-A</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. HCC4006, HCC827, HCC2935 and H3255 cells were transduced with control (AdCont) or RHOB-overexpressing (AdRHOB) adenoviruses and treated for four hours with erlotinib at concentrations corresponding to the respective IC50 values determined for each control cell line. The phosphorylation status of AKT, ERK1/2 and EGFR was assessed by western blotting and normalized according to total protein levels. RHOB overexpression was also monitored by western blotting.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_4-B</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Representative immunostaining of phospho-AKT (Ser473), phospho ERK1/2 and their total protein amounts in lung tumors from EGFRL858R/Rhob-/- or EGFRL858R/Rhob+/+ mice treated or not with erlotinib (12.5 mg/kg/day) for four days. The remaining hyperplastic areas were selected in erlotinib-treated mice to efficiently characterize the effect of erlotinib on ERK and AKT pathways in both Rhob genotypes. Scale bar: 100 &#181;m.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_4-C-1</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 4-C-1</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C-1</infon>
    <passage>
      <offset>0</offset>
      <text>C. HCC4006 cells were transfected with a plasmid coding for a constitutively active AKT mutant (AKTmyr, myristoylated) or an empty vector (&#248;), and treated for 72 h with increasing concentrations of erlotinib. The surviving cell fraction was determined by an MTS assay. Data are representative of at least three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_4-C-2</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 4-C-2</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C-2</infon>
    <passage>
      <offset>0</offset>
      <text>C. HCC4006 cells were transfected with a plasmid coding for a constitutively active AKT mutant (AKTmyr, myristoylated) or an empty vector (&#248;), and treated for 72 h with increasing concentrations of erlotinib. AKT overexpression and phosphorylation at Ser473 were assessed by western blotting. Data are representative of at least three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_5-A</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing (AdRHOB) adenoviruses and treated for four hours with erlotinib (100 nM), G594 (100 nM), or a combination of both drugs. The phosphorylation status of GSK3&#946; (Ser9), ERK1/2 and EGFR (Tyr1173) was assessed by western blotting and normalized according to the total protein levels. RHOB overexpression was also monitored by western blotting.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_5-B</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing (AdRHOB) adenoviruses and treated for 72 h with erlotinib alone (black and red curves) or in combination with the AKT inhibitor G594 at 100 nM (green and blue curves). The surviving cell fraction was determined by an MTS assay.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_5-C</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing adenoviruses (AdRHOB) and treated for 72 h with increasing concentrations of erlotinib in the absence or presence of increasing doses of G594. The surviving cell fraction was determined by an MTS assay, and erlotinib IC50 values were determined for each condition. (**: p&lt;0.001 vs. AdCont cells; ***: p&lt;0.0001 vs. AdCont cells). HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing (AdRHOB) adenoviruses and treated for 48 h with erlotinib (100 nM), G594 (100 nM), or a combination of both drugs.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_5-D</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing (AdRHOB) adenoviruses and treated for 48 h with erlotinib (100 nM), G594 (100 nM), or a combination of both drugs. Apoptosis was then determined by quantification of the subG1 cell population (D).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_5-E</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>HCC4006 cells were transduced with control (AdCont) or RHOB-overexpressing (AdRHOB) adenoviruses and treated for 48 h with erlotinib (100 nM), G594 (100 nM), or a combination of both drugs. Apoptosis was then determined by detection of cleaved PARP and caspase-3 (E).</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_6-A-B</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 6-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A. Representative H&amp;E staining of lung tumors from EGFRL858R/Rhob-/-, EGFRL858R/Rhob+/- and EGFRL858R/Rhob+/+ mice treated or not during four days with erlotinib (12.5 mg/kg/day), with the AKT inhibitor G594 (25 mg/kg/day), or in combination with both drugs. Scale bar: 500 &#181;m. B. Quantification of the tumor/lung ratio of mice treated or not with the individual drugs or with a combination of both.</text>
    </passage>
  </document>
  <document>
    <id>5286377 Figure_6-C-D</id>
    <infon key="sourcedata_document">2605</infon>
    <infon key="doi">10.15252/emmm.201606646</infon>
    <infon key="pmc_id">5286377</infon>
    <infon key="figure">Figure 6-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C. Representative Ki67 immunostaining of lung tumors from EGFRL858R/Rhob-/-, EGFRL858R/Rhob+/- and EGFRL858R/Rhob+/+ mice treated or not with erlotinib alone (12.5 mg/kg/day) or in combination with the AKT inhibitor G594 (25 mg/kg/day) for four days (scale bar: 50 &#181;m), and the corresponding quantification (D).</text>
    </passage>
  </document>
</collection>
